The NHS does not buy technology. It buys trust.

Most software and AI companies approach the NHS as a sales problem. Sharper positioning, a better demo, a more persuasive deck. Then the pipeline fills with enthusiastic clinicians and nothing closes, and quarters disappear. The problem is rarely the product. The buyer is not deciding whether your product is good. They are deciding whether adopting it is safe for them personally and affordable for their organisation this year.

Three consequences follow, and most companies learn them the expensive way. Your first customer is not the trust, it is Information Governance. Your real competitor is not another vendor, it is the status quo and the cost of change. And a pilot without an agreed scaling budget is not a sales strategy, it is funded market research. This paper is about selling into a system that runs on those three facts.

What is inside

• Why companies fail, and how buying actually works: no single buyer, standards national, money regional, and the who-pays-versus-who-benefits problem that sinks strong-ROI products
• Who holds power: the stakeholder map, the clinical champion, and why Information Governance is your first customer
• The assurance stack to be deployable: medical-device status, DCB0129 clinical safety, DSPT, the AI model-training trap, DTAC, interoperability, and net zero and social value
• Evidence and the business case that make you sellable, not just deployable
• The route to market: frameworks, G-Cloud and Spark DPS, Atamis, and the competition you are actually against
• Pilotitis and a five-level readiness maturity model, plus the 2025 to 2027 reform moving the whole map

Who it is for

Founders and commercial leaders of growth-stage software and AI companies selling into the NHS in England. Boards and investors who want an honest read on whether a portfolio company is legally deployable and commercially viable, and where the next gate sits. It is a commercial field guide, not regulatory or legal advice.

Written from an operating perspective

Four exits over three decades (Lotus to IBM, Paragon to Phone.com, Apertio to Nokia $240M, Clearswift to Lyceum) plus CGO and COO seats in digital health and life sciences at Sapio Sciences and Lumeon. Every section is drawn from a real deal that either worked or stalled for a reason the diagnostic would have surfaced.